Efficacy and clinical application of Seladelpar

Seladelpar (Seladelpar) is an innovative drug mainly used to treat primary biliary cholangitis (PBC) . PBC is a chronic autoimmune liver disease that mainly affects the bile ducts of the liver, causing obstruction of bile flow and causing bile duct damage. As the disease progresses, patients may develop liver failure, cirrhosis, or even liver cancer. The introduction of Siladepa provides a new treatment option for the treatment of this disease, especially when ursodeoxycholic acid (UDCA) is ineffective or patients cannot tolerate UDCA.

Siladepa is a selective peroxisome proliferator-activated receptor-δ (PPAR-δ) agonist. Its main function is to regulate lipid metabolism, reduce liver inflammation and promote bile production by activating the PPAR-δ pathway. As a nuclear receptor, PPAR-δ plays an important role in multiple physiological processes, especially in the regulation of lipid metabolism, inflammatory response, and fibrosis. By regulating this pathway, Siladepa can effectively relieve bile duct inflammation, reduce fat accumulation in the liver, and inhibit the progression of fibrosis.

Clinical studies have shown that Siladepa has significant efficacy in patients with primary biliary cholangitis. In clinical trials, patients taking Seradepa showed significant biochemical improvements, particularly in liver function markers such as alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT). Siladepa can effectively reduce ALP levels by improving bile flow in the liver and reducing bile duct damage, which is also an important marker for measuring the progression of PBC. Compared with other treatment options, Siladepa has demonstrated good efficacy in reducing ALP levels, reducing liver inflammation and controlling the disease.

Due to its good efficacy and wide range of indications, Siladepa is widely used in the treatment of PBCEspecially in patients with poor response to UDCA treatment or poor tolerance to UDCA, it has become an important treatment option.

Keyword tags: Seladelpar, Seladelpar, primary biliary cholangitis, PBC, PPAR-δ agonist, bile production, improvement of liver function, UDCA combination therapy

References:https://www.ema.europa.eu/en/medicines/human/EPAR/lyvdelzi